Corient Private Wealth LLC Lowers Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Corient Private Wealth LLC lessened its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 71.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,779 shares of the biopharmaceutical company's stock after selling 14,464 shares during the period. Corient Private Wealth LLC's holdings in Halozyme Therapeutics were worth $276,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in HALO. CBIZ Investment Advisory Services LLC bought a new position in Halozyme Therapeutics during the fourth quarter valued at $29,000. Heck Capital Advisors LLC purchased a new stake in shares of Halozyme Therapeutics during the 4th quarter valued at about $29,000. Smartleaf Asset Management LLC lifted its holdings in shares of Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after acquiring an additional 197 shares during the last quarter. Venturi Wealth Management LLC purchased a new position in Halozyme Therapeutics in the fourth quarter worth about $69,000. Finally, Parkside Financial Bank & Trust increased its stake in Halozyme Therapeutics by 21.8% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after acquiring an additional 322 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

Insider Buying and Selling

In other news, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the sale, the director now directly owns 38,611 shares in the company, valued at approximately $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Michael J. Labarre sold 10,000 shares of the business's stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total value of $580,500.00. Following the sale, the senior vice president now owns 185,453 shares in the company, valued at approximately $10,765,546.65. The trade was a 5.12 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 32,200 shares of company stock worth $1,786,668 in the last 90 days. 2.90% of the stock is owned by corporate insiders.

Remove Ads

Halozyme Therapeutics Stock Down 3.5 %

Shares of HALO traded down $2.15 during mid-day trading on Friday, hitting $59.77. The company's stock had a trading volume of 2,295,325 shares, compared to its average volume of 1,393,194. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. The company's 50-day moving average is $59.82 and its 200-day moving average is $54.93. Halozyme Therapeutics, Inc. has a 52-week low of $37.73 and a 52-week high of $66.00. The firm has a market capitalization of $7.38 billion, a price-to-earnings ratio of 17.43, a PEG ratio of 0.42 and a beta of 1.32.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping analysts' consensus estimates of $1.17 by $0.02. The company had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. On average, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently commented on HALO. Wells Fargo & Company dropped their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Benchmark reaffirmed a "buy" rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Piper Sandler increased their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research report on Friday, January 10th. Finally, HC Wainwright restated a "buy" rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $62.78.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.